Rigel(RIGL)

Search documents
Rigel(RIGL) - 2025 Q2 - Earnings Call Presentation
2025-08-05 20:30
Financial Performance & Guidance - Q2 2025 net product sales reached $58.9 million[81] - Q2 2025 contract revenues from collaborations totaled $42.7 million[81] - Rigel increased its 2025 net product sales guidance to a range of $210 million to $220 million, up from the previous guidance of $185 million to $192 million[14, 86] - The company anticipates total revenue for 2025 to be approximately $270 million to $280 million, revised from the initial estimate of $200 million to $210 million[85] - Rigel reported net product sales of $102.5 million YTD[15] Product Performance - Q2 2025 net product sales for TAVALISSE were $40.1 million[26, 83] - Q2 2025 net product sales for GAVRETO were $11.8 million[29, 83] - Q2 2025 net product sales for REZLIDHIA were $7.0 million[29, 83] R&D and Clinical Development - Rigel is evaluating R289, a dual IRAK1/4 inhibitor, in a Phase 1b study for relapsed/refractory lower-risk MDS[13] - The company plans to initiate a Phase 2 study of olutasidenib in recurrent glioma[13] Strategic Collaborations - Collaboration revenues included $40.0 million from Eli Lilly[83] - Grifols contributed $2.0 million in collaboration revenue[35, 83] - Kissei contributed $0.4 million in collaboration revenue[35, 83] - Medison contributed $0.2 million in collaboration revenue[35, 83]
Rigel(RIGL) - 2025 Q2 - Quarterly Report
2025-08-05 20:05
PART I FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Rigel Pharmaceuticals' unaudited condensed consolidated financial statements for periods ending June 30, 2025, are presented, covering balance sheets, income statements, and cash flows Condensed Balance Sheet Highlights (in thousands) | Account | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $53,407 | $56,746 | | Total current assets | $175,393 | $135,103 | | Total assets | $206,736 | $163,976 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $86,636 | $63,299 | | Total liabilities | $124,802 | $160,688 | | Total stockholders' equity | $81,934 | $3,288 | Condensed Statements of Operations Highlights (in thousands, except per share data) | Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | Six Months Ended June 30, 2025 (in thousands) | Six Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $101,685 | $36,841 | $155,018 | $66,375 | | Income (loss) from operations | $61,103 | $447 | $73,876 | $(6,519) | | Net income (loss) | $59,613 | $(1,030) | $71,059 | $(9,277) | | Diluted EPS | $3.28 | $(0.06) | $3.91 | $(0.53) | Condensed Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2025 (in thousands) | Six Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $29,644 | $(4,711) | | Net cash (used in) provided by investing activities | $(33,828) | $11,242 | | Net cash provided by (used in) financing activities | $902 | $(3,264) | | Net (decrease) increase in cash | $(3,282) | $3,267 | [Notes to Condensed Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) Detailed notes cover accounting policies, revenue, collaborations, and debt, including the **$40.0 million** Lilly cost share release - The company's commercial portfolio includes three FDA-approved products: TAVALISSE® (fostamatinib), REZLIDHIA® (olutasidenib), and GAVRETO® (pralsetinib), which began commercialization in June 2024[20](index=20&type=chunk)[21](index=21&type=chunk)[22](index=22&type=chunk) - As of June 30, 2025, the company had **$108.4 million** in cash, cash equivalents, and short-term investments and believes these funds are sufficient to support operations for at least the next 12 months[28](index=28&type=chunk)[29](index=29&type=chunk) Disaggregated Revenue (in thousands) | Revenue Category | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Total product sales, net | $58,948 | $33,450 | $102,498 | $59,453 | | Revenues from collaborations | $42,737 | $3,391 | $52,520 | $6,922 | | **Total revenues** | **$101,685** | **$36,841** | **$155,018** | **$66,375** | - On April 30, 2025, Rigel notified Eli Lilly of its decision not to exercise its opt-in right for co-funding ocadusertib development, resulting in the recognition of **$40.0 million** in contract revenue in Q2 2025 from the released cost share liability[51](index=51&type=chunk) - The company acquired the US rights to GAVRETO from Blueprint in February 2024 for a purchase price of **$15.0 million** plus potential future milestones and royalties, accounted for as an asset acquisition[69](index=69&type=chunk)[72](index=72&type=chunk) - As of June 30, 2025, the company had **$60.0 million** in principal outstanding from its credit facility with MidCap, maturing on September 1, 2027, with an interest-only period extending through October 1, 2025[99](index=99&type=chunk)[100](index=100&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=41&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes Q2 and H1 2025 financial results, detailing revenue growth, operating expenses, liquidity, and capital resources [Business Updates](index=42&type=section&id=Business%20Updates) This section details commercial performance of key products, showing significant sales growth, and outlines clinical pipeline progress Net Product Sales Growth - H1 2025 vs H1 2024 | Product | H1 2025 Net Sales (in millions) | H1 2024 Net Sales (in millions) | Increase ($ in millions) | Increase (%) | | :--- | :--- | :--- | :--- | :--- | | TAVALISSE | $68.5 million | $47.5 million | $21.1 million | 44% | | REZLIDHIA | $13.1 million | $10.0 million | $3.1 million | 31% | | GAVRETO | $20.8 million | $1.9 million | $18.9 million | 995% | - The Phase 1b study of R289, an oral IRAK 1/4 inhibitor for lower-risk MDS, completed enrollment in its dose escalation part in July 2025, with updated data and dose expansion planned for the second half of 2025[132](index=132&type=chunk)[133](index=133&type=chunk) - Rigel opted out of future co-funding obligations for the ocadusertib program with Lilly, resulting in the release of a **$40.0 million** cost share liability, recognized as revenue in Q2 2025[139](index=139&type=chunk) [Results of Operations](index=63&type=section&id=Results%20of%20Operations) Operations analysis shows significant Q2 and H1 2025 revenue increases from collaborations and product sales, alongside rising operating expenses Revenue Analysis (in thousands) | Revenue Type | Q2 2025 (in thousands) | Q2 2024 (in thousands) | Change (in thousands) | H1 2025 (in thousands) | H1 2024 (in thousands) | Change (in thousands) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Product sales, net | $58,948 | $33,450 | $25,498 | $102,498 | $59,453 | $43,045 | | Contract revenues | $42,737 | $3,391 | $39,346 | $52,520 | $6,922 | $45,598 | | **Total revenues** | **$101,685** | **$36,841** | **$64,844** | **$155,018** | **$66,375** | **$88,643** | - The substantial increase in contract revenues for Q2 and H1 2025 was primarily due to the **$40.0 million** non-cash revenue related to the release of the cost share liability from the Lilly collaboration[200](index=200&type=chunk) - Research and development expenses increased by **$3.7 million (32%)** in H1 2025 compared to H1 2024, mainly driven by higher clinical trial costs for the olutasidenib and IRAK 1/4 inhibitor programs[208](index=208&type=chunk) - Selling, general and administrative expenses increased slightly by **$0.5 million (1%)** in H1 2025 compared to H1 2024, with increased personnel costs largely offset by decreased consulting services and stock-based compensation expense[219](index=219&type=chunk) [Liquidity and Capital Resources](index=71&type=section&id=Liquidity%20and%20Capital%20Resources) Rigel held **$108.4 million** in cash as of June 30, 2025, with sufficient liquidity for 12 months, driven by positive operating cash flow Cash Flow Summary (in thousands) | Activity | Six Months Ended June 30, 2025 (in thousands) | Six Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | | Net cash from Operating activities | $29,644 | $(4,711) | | Net cash from Investing activities | $(33,828) | $11,242 | | Net cash from Financing activities | $902 | $(3,264) | - The company has a contractual manufacturing obligation for TAVALISSE that could potentially result in cancellation fees of approximately **$22.5 million**, with **$3.0 million** expected to be due in the remainder of 2025[243](index=243&type=chunk) - Future minimum principal payments on the outstanding **$60.0 million** loan are **$7.5 million** for the remainder of 2025, **$30.0 million** for 2026, and **$22.5 million** for 2027[103](index=103&type=chunk)[249](index=249&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=79&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes occurred in the company's market risk disclosures, including interest rate sensitivities, since December 31, 2024 - There were no material changes to the company's market risk disclosures during the six months ended June 30, 2025[252](index=252&type=chunk) [Controls and Procedures](index=79&type=section&id=Item%204.%20Controls%20and%20Procedures) The CEO and CFO concluded disclosure controls were effective, with no material changes to internal control over financial reporting this quarter - The principal executive officer and principal financial officer concluded that as of June 30, 2025, the company's disclosure controls and procedures were effective[253](index=253&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[254](index=254&type=chunk) PART II OTHER INFORMATION [Legal Proceedings](index=80&type=section&id=Item%201.%20Legal%20Proceedings) Rigel settled patent litigation with Annora Pharma in March 2025, resolving disputes over a generic TAVALISSE version - The company settled patent litigation with Annora concerning a generic version of TAVALISSE, allowing Annora to sell its generic product in Q2 2032 or earlier under certain circumstances[259](index=259&type=chunk) [Risk Factors](index=81&type=section&id=Item%201A.%20Risk%20Factors) This section outlines key risks, including product commercial success dependence, clinical failures, competition, regulatory challenges, and manufacturing reliance - The company's prospects are highly dependent on the commercial success of its three products: TAVALISSE, REZLIDHIA, and GAVRETO, with any diminishment adversely affecting the business[263](index=263&type=chunk)[500](index=500&type=chunk) - There is a high risk that drug discovery and development efforts may not generate successful product candidates, and clinical trial failures could harm commercial prospects and delay or eliminate revenue generation[263](index=263&type=chunk)[274](index=274&type=chunk) - The company faces risks from potential generic versions of its products, such as TAVALISSE, which could significantly decrease revenue, following a settlement allowing a generic version to market in Q2 2032 or earlier[328](index=328&type=chunk)[329](index=329&type=chunk) - The business is subject to stringent and evolving privacy and information security laws (e.g., GDPR, CCPA), and failure to comply could result in significant fines, penalties, and reputational harm[287](index=287&type=chunk) - The company lacks its own manufacturing capabilities and relies on third-party manufacturers, exposing it to risks of supply disruption, quality control issues, and regulatory compliance failures[266](index=266&type=chunk)[473](index=473&type=chunk) [Other Information Items (Items 2-6)](index=185&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section covers procedural items, including no unregistered equity sales, no defaults on senior securities, and no Rule 10b5-1 trading plan changes - The company reported no unregistered sales of equity securities, use of proceeds, or defaults upon senior securities for the period[551](index=551&type=chunk)[552](index=552&type=chunk) - No directors or executive officers adopted or terminated a Rule 10b5-1 trading plan or a non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2025[554](index=554&type=chunk)
Rigel(RIGL) - 2025 Q2 - Quarterly Results
2025-08-05 20:03
[Financial & Business Highlights](index=1&type=section&id=Financial%20%26%20Business%20Highlights) Rigel's Q2 2025 featured 76% net product sales growth, $59.6 million net income, increased cash, and raised full-year guidance Key Financial Highlights | Metric | Q2 2025 ($ millions) | YoY Change | | :--- | :--- | :--- | | Net Product Sales | $58.9 | +76% | | Total Revenue | $101.7 | N/A | | Net Income | $59.6 | From Net Loss | | Cash & Equivalents | $108.4 | +40% vs Dec 2024 | - The company raised its 2025 total revenue guidance to a range of **$270 to $280 million**, a significant increase from the previous guidance of **$200 to $210 million**[3](index=3&type=chunk)[6](index=6&type=chunk)[17](index=17&type=chunk) - Enrollment was completed in the dose escalation part of the Phase 1b study for R289, a dual IRAK1/4 inhibitor for patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS)[3](index=3&type=chunk)[5](index=5&type=chunk)[6](index=6&type=chunk) [Business Update](index=1&type=section&id=Business%20Update) Rigel opted out of ocadusertib co-development, recognizing $40.0 million non-cash revenue, and advanced R289 clinical trials [Commercial & Corporate](index=1&type=section&id=Commercial%20%26%20Corporate) Rigel opted out of ocadusertib co-development, recognizing **$40.0 million** non-cash revenue, and Kissei launched TAVALISSE in South Korea - Rigel notified Eli Lilly it would not exercise its opt-in right for ocadusertib, resulting in the recognition of **$40.0 million** in non-cash revenue from the release of a cost-share liability, with Rigel remaining entitled to future milestones and royalties[4](index=4&type=chunk) - Rigel's partner, Kissei Pharmaceutical, announced the commercial launch of TAVALISSE in South Korea in early July through its licensing partner, JW Pharmaceutical Corporation[7](index=7&type=chunk) [Clinical Development & Publications](index=1&type=section&id=Clinical%20Development%20%26%20Publications) R289 Phase 1b dose escalation completed, with expansion planned; GAVRETO and REZLIDHIA data presented; and olutasidenib papers published - Enrollment in the dose escalation part of the Phase 1b study for R289 in patients with lower-risk MDS was completed in July, with plans to share updated data and initiate the dose expansion part later in the year[5](index=5&type=chunk) - Rigel presented **4 posters** at the ASCO Annual Meeting and **3 posters** at the EHA Congress, including final data for GAVRETO in NSCLC and supportive data for REZLIDHIA in AML[8](index=8&type=chunk) - Key publications included a paper in *Leukemia & Lymphoma* on the effectiveness of olutasidenib versus ivosidenib and a paper in *Blood Advances* on olutasidenib's use in MDS[12](index=12&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) Rigel's Q2 2025 total revenues reached **$101.7 million**, with **$59.6 million** net income, a significant turnaround from prior year loss [Q2 2025 Performance](index=2&type=section&id=Q2%202025%20Performance) Q2 2025 total revenue reached **$101.7 million**, with **$59.6 million** net income, driven by product sales and a **$40 million** non-cash revenue Q2 Revenue Breakdown | Revenue Source | Q2 2025 ($ millions) | Q2 2024 ($ millions) | | :--- | :--- | :--- | | Net Product Sales | $58.9 | $33.5 | | Contract Revenues | $42.7 | $3.4 | | **Total Revenues** | **$101.7** | **$36.8** | Q2 Product Net Sales | Product | Q2 2025 Net Sales ($ millions) | YoY Growth | | :--- | :--- | :--- | | TAVALISSE | $40.1 | +52% | | GAVRETO | $11.8 | N/A (Launched June 2024) | | REZLIDHIA | $7.0 | +36% | Q2 Net Income (Loss) and EPS | Metric | Q2 2025 ($ millions) | Q2 2024 ($ millions) | | :--- | :--- | :--- | | Net Income (Loss) | $59.6 | ($1.0) | | Diluted EPS | $3.28 | ($0.06) | [Year-to-Date (YTD) 2025 Performance](index=3&type=section&id=Year-to-Date%20%28YTD%29%202025%20Performance) YTD 2025 total revenues reached **$155.0 million**, with **$71.1 million** net income, and cash increased to **$108.4 million** YTD Revenue Breakdown | Revenue Source | YTD 2025 ($ millions) | YTD 2024 ($ millions) | | :--- | :--- | :--- | | Net Product Sales | $102.5 | $59.5 | | Contract Revenues | $52.5 | $6.9 | | **Total Revenues** | **$155.0** | **$66.4** | YTD Net Income (Loss) and EPS | Metric | YTD 2025 ($ millions) | YTD 2024 ($ millions) | | :--- | :--- | :--- | | Net Income (Loss) | $71.1 | ($9.3) | | Diluted EPS | $3.91 | ($0.53) | - Cash, cash equivalents and short-term investments increased to **$108.4 million** as of June 30, 2025, compared to **$77.3 million** as of December 31, 2024[16](index=16&type=chunk) [2025 Financial Outlook](index=3&type=section&id=2025%20Financial%20Outlook) Rigel significantly raised its full-year 2025 total revenue guidance to **$270-$280 million**, anticipating positive net income 2025 Financial Guidance Update | 2025 Guidance | Updated Range ($ millions) | Previous Range ($ millions) | | :--- | :--- | :--- | | Total Revenue | $270 - $280 | $200 - $210 | | Net Product Sales | $210 - $220 | $185 - $192 | | Contract Revenues | ~$60 | $15 - $18 | - The company anticipates it will report positive net income for the full year 2025[17](index=17&type=chunk) - The total revenue and contract revenue guidance includes **$40 million** in non-cash contract revenue related to the agreement with Lilly[17](index=17&type=chunk) [Product & Disease Area Overview](index=4&type=section&id=Product%20%26%20Disease%20Area%20Overview) This section outlines Rigel's three commercial products—TAVALISSE, GAVRETO, and REZLIDHIA—and their respective target diseases [Marketed Products](index=4&type=section&id=Marketed%20Products) Rigel's portfolio includes three FDA-approved products: TAVALISSE for ITP, GAVRETO for RET fusion-positive cancers, and REZLIDHIA for IDH1-mutated AML - TAVALISSE (fostamatinib) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment[25](index=25&type=chunk) - GAVRETO (pralsetinib) is indicated for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer[26](index=26&type=chunk) - REZLIDHIA (olutasidenib) is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation[28](index=28&type=chunk) [Target Disease Areas](index=4&type=section&id=Target%20Disease%20Areas) This section describes the target diseases: Immune Thrombocytopenia (ITP), RET fusion-positive NSCLC, and Acute Myeloid Leukemia (AML) - In Immune Thrombocytopenia (ITP), the immune system destroys blood platelets, leading to a risk of severe bleeding, with a significant medical need remaining for patients who do not respond to existing therapies[21](index=21&type=chunk) - Non-small cell lung cancer (NSCLC) accounts for **85-90%** of all lung cancers, with RET fusions implicated in approximately **1-2%** of patients[22](index=22&type=chunk) - Acute Myeloid Leukemia (AML) is a rapidly progressing blood cancer, with an unmet need for well-tolerated treatments for patients with relapsed or refractory disease[23](index=23&type=chunk)[24](index=24&type=chunk) [Financial Statements](index=7&type=section&id=Financial%20Statements) This section presents detailed, unaudited financial statements for Q2 and YTD 2025, including Statements of Operations and a Summary Balance Sheet [Statements of Operations](index=7&type=section&id=Statements%20of%20Operations) The Statements of Operations provides a detailed income statement for Q2 and YTD 2025, breaking down revenues, expenses, and net income/loss Consolidated Statements of Operations (Unaudited) | (in thousands, except per share) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | **Total revenues** | **$101,685** | **$36,841** | **$155,018** | **$66,375** | | Total costs and expenses | $40,582 | $36,394 | $81,142 | $72,894 | | Income (loss) from operations | $61,103 | $447 | $73,876 | ($6,519) | | **Net income (loss)** | **$59,613** | **($1,030)** | **$71,059** | **($9,277)** | | Diluted net income (loss) per share | $3.28 | ($0.06) | $3.91 | ($0.53) | [Summary Balance Sheet Data](index=7&type=section&id=Summary%20Balance%20Sheet%20Data) The Summary Balance Sheet presents key figures as of June 30, 2025, highlighting increased cash to **$108.4 million** and stockholders' equity to **$81.9 million** Summary Balance Sheet Data (Unaudited) | (in thousands) | As of June 30, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents and short-term investments | $108,378 | $77,321 | | Total assets | $206,736 | $163,976 | | Stockholders' equity | $81,934 | $3,288 |
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
Prnewswire· 2025-08-05 20:01
Core Insights - Rigel Pharmaceuticals reported a strong second quarter in 2025, with a 76% year-over-year increase in net product sales, reaching $58.9 million, and a net income of $59.6 million [2][5][7] Financial Performance - Total revenues for Q2 2025 were $101.7 million, comprising $58.9 million in net product sales and $42.7 million in contract revenues from collaborations [5][10] - Net product sales grew significantly, with TAVALISSE sales at $40.1 million (up 52% from $26.4 million in Q2 2024), GAVRETO at $11.8 million (up from $1.9 million), and REZLIDHIA at $7.0 million (up 36% from $5.2 million) [5][11] - For the first half of 2025, total revenues were $155.0 million, with net product sales of $102.5 million, reflecting a 72% increase compared to the same period in 2024 [8][9] Cost and Expenses - Total costs and expenses for Q2 2025 were $40.6 million, an increase from $36.4 million in Q2 2024, primarily due to higher product sales costs and increased R&D expenses [6][9] - The company reported a net income of $59.6 million for Q2 2025, compared to a net loss of $1.0 million in Q2 2024 [7][12] Business Developments - Rigel completed enrollment in the dose escalation part of its Phase 1b study evaluating R289 in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS) [2][11] - The company updated its 2025 financial guidance, projecting total revenue of approximately $270 to $280 million, an increase from the previous estimate of $200 to $210 million [10][13] Collaborations and Agreements - Rigel recognized $40.0 million in non-cash revenue from the release of the remaining cost share liability related to its agreement with Eli Lilly for the development of ocadusertib [3][5] - The company continues to receive milestone and tiered royalty payments on future net sales of ocadusertib as part of its agreement with Lilly [3]
Why Rigel (RIGL) Could Beat Earnings Estimates Again
ZACKS· 2025-07-30 17:11
Core Insights - Rigel Pharmaceuticals has a strong track record of beating earnings estimates, with an average surprise of 197.73% over the last two quarters [1] - The company reported earnings of $0.14 per share for the most recent quarter, exceeding expectations by 350.00%, while the previous quarter's earnings were $0.80 per share against an estimate of $0.55, resulting in a surprise of 45.45% [2] Earnings Estimates and Predictions - Recent estimates for Rigel have been increasing, with a positive Earnings ESP of +23.86%, indicating bullish sentiment among analysts regarding the company's earnings prospects [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a high likelihood of another earnings beat in the upcoming report scheduled for August 5, 2025 [8] Earnings ESP and Market Behavior - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced positive surprises nearly 70% of the time, indicating a strong correlation between these metrics and earnings performance [6] - The Earnings ESP metric compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may provide more accurate predictions [7]
Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect?
ZACKS· 2025-07-30 14:55
Group 1 - Rigel Pharmaceuticals (RIGL) closed at $19.9, with a 6.4% gain over the past four weeks, and a mean price target of $33.74 suggests a 69.6% upside potential [1] - The average price target ranges from a low of $20.45 to a high of $57.00, with a standard deviation of $17.29, indicating variability among analysts' estimates [2] - Analysts show strong agreement on RIGL's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for RIGL's current year earnings has increased by 19%, with no negative revisions [12] - RIGL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of RIGL's potential gain, it does provide a directional guide for price movement [14]
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
ZACKS· 2025-07-30 14:41
Core Viewpoint - The article emphasizes the importance of value investing and highlights Rigel Pharmaceuticals (RIGL) and USANA Health Sciences (USNA) as strong value stock picks based on their financial metrics and Zacks Rank [2][3][8]. Company Analysis Rigel Pharmaceuticals (RIGL) - RIGL holds a Zacks Rank of 2 (Buy) and has a Value grade of A, indicating strong potential as a value stock [3]. - The company has a Price-to-Sales (P/S) ratio of 1.75, significantly lower than the industry average of 3.73, suggesting it may be undervalued [4]. - RIGL's Price-to-Cash Flow (P/CF) ratio is 9.33, compared to the industry average of 12.83, indicating a favorable cash outlook [5]. - Over the past year, RIGL's P/CF has fluctuated between a high of 96.38 and a low of -21.56, with a median of 10.07 [5]. USANA Health Sciences (USNA) - USNA also has a Zacks Rank of 2 (Buy) and a Value grade of A, making it another strong candidate for value investing [6]. - The stock is currently trading at a forward earnings multiple of 10.25 and a PEG ratio of 0.85, both significantly lower than the industry averages of 41.97 and 1.96, respectively [6]. - Over the last 12 months, USNA's P/E ratio has ranged from a high of 17.00 to a low of 7.83, with a median of 11.15, indicating potential undervaluation [7]. - USNA's Price-to-Book (P/B) ratio is 1.10, compared to the industry's 1.64, further supporting its value proposition [7].
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
Prnewswire· 2025-07-29 12:05
Core Viewpoint - Rigel Pharmaceuticals, Inc. will report its second quarter 2025 financial results on August 5, 2025, followed by a live conference call to discuss the results and business updates [1] Company Information - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for hematologic disorders and cancer, founded in 1996 and based in South San Francisco, California [3]
Rigel Pharmaceuticals (RIGL) Earnings Call Presentation
2025-07-03 13:13
Financial Performance - Total net product sales for Q2 2024 were $33.5 million[148] - TAVALISSE net product sales for Q2 2024 were $26.4 million[34, 148], representing a 25% growth compared to Q2 2023[34] and 8% growth compared to Q1 2024[34] - REZLIDHIA net product sales for Q2 2024 were $5.2 million[65, 148], a 102% increase compared to Q2 2023[65] and a 5% increase compared to Q1 2024[65] - GAVRETO net product sales for Q2 2024 were $1.9 million[96, 148] Product Sales and Growth - TAVALISSE bottles shipped to patients and clinics in Q2 2024 totaled 2,672[34], an 18% increase compared to Q2 2023[33] and a 24% increase compared to Q1 2024[34] - REZLIDHIA bottles shipped to patients and clinics in Q2 2024 totaled 424[64], a 127% increase compared to Q2 2023[64] and a 30% increase compared to Q1 2024[64] - 228 GAVRETO 60 ct eq bottles were sold in Q2 2024[96] Clinical Development and Collaborations - Rigel and The University of Texas MD Anderson Cancer Center will evaluate olutasidenib in combination with other agents to treat newly-diagnosed and relapsed/refractory patients with IDH1-mutated AML[106] - Rigel will provide funding up to $3 million and study material over the 4-year collaboration with CONNECT to Advance Olutasidenib in Glioma[115]
Rigel Pharmaceuticals (RIGL) 2025 Conference Transcript
2025-06-04 17:50
Summary of Rigel's Conference Call Company Overview - **Company**: Rigel Pharmaceuticals - **Industry**: Hematology and Oncology Core Business and Products - Rigel aims to grow its hematology and oncology business with three approved products: - **TAVALISSE** for Immune Thrombocytopenic Purpura (ITP) - **Reslidia** for mutant IDH1 relapsed and refractory Acute Myeloid Leukemia (AML) - **GAVRETO** for RET fusion positive non-small cell lung cancer and thyroid cancer - The company has achieved profitability and plans to maintain it while investing in development opportunities [2][4][60] Financial Performance - Rigel's commercial business has shown a **32% CAGR** since emerging from COVID-19, driven by TAVALISSE and the recent acquisition of GAVRETO [5][6] - Projected net product sales for the current year are between **$185 million and $192 million**, indicating continued growth [5][60] - Q1 sales for TAVALISSE reached **$28 million**, reflecting a **35% year-over-year growth** [6] Product Development and Pipeline - Rigel is developing **R289**, a dual IRAK1 and IRAK4 inhibitor, currently in a Phase 1b study for lower risk MDS, with potential for significant impact on patient care [3][27] - Plans to expand the use of **oludasidenib** beyond mutant IDH1 AML to include glioma trials later this year [4][27] - Rigel is actively seeking in-licensing and acquisition opportunities for late-stage products in hematology and oncology [4][28] Market Dynamics and Competitive Position - TAVALISSE is gaining traction in the treatment of ITP, with a growing patient base and improved treatment paradigms [11][13] - Reslidia shows promising clinical data with a **35% CR/CRH rate** and a durability of response lasting nearly **26 months**, significantly better than previous treatments [17][19] - GAVRETO has captured about **50% market share** in its category, with efforts to convert patients from less effective treatments [21][22] Clinical Trials and Research - Rigel is focusing on the treatment of transfusion-dependent lower risk MDS patients, with a unique mechanism of action targeting inflammatory pathways [31][32] - The company has initiated a Phase II study for oludasidenib in glioma, collaborating with MD Anderson for broader research opportunities [56][58] Financial Outlook - Rigel anticipates total revenue between **$200 million and $210 million** for the year, with a continued focus on financial discipline and cash flow generation [60][61] - The company is committed to funding its development programs through its own cash flow, maintaining a strong financial position [60][62] Conclusion - Rigel is positioned for significant growth in the hematology and oncology sectors, with a robust product portfolio, promising clinical developments, and a strong financial outlook, making it an attractive opportunity for investors [62]